U.S. approves Pfizer vaccine for emergency use

U.S. approves Pfizer vaccine for emergency use

The leadership of the federal Centers for Disease Control and Prevention (CDC) has approved the use of a BioNTech/Pfizer vaccine in the United States in emergency circumstances. It was announced on the CDC’s Twitter page.

“The CDC approved the immunization committee’s recommendation to authorize the first use of the COVID-19 vaccine for people 16 years of age and older. Health care workers and patients in long-term care facilities are to be vaccinated first,” the regulator clarified in a statement.

The vaccine is now officially available in the United States. The first shipments to various cities and states (636 locations) will be delivered shortly.

The FDA recommended Friday, Dec. 11, that the administration approve the Pfizer/BioNTech coronavirus vaccine. FDA experts called for approval of the vaccine’s fast-track emergency registration.

To date, there are several vaccines against COVID-19 in the world. Thus, two vaccines have been registered in Russia: Sputnik V and EpiVacCorona. On December 5, vaccination against coronavirus with Sputnik V started in Moscow. A COVID-19 vaccine produced by Pfizer/BioNTech has been registered in the U.S., with another Moderna vaccine on the way. Also, the British pharmaceutical company AstraZeneca announced the start of clinical trials of a combination of its AZD1222 vaccine.